Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician’s choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2−) metastatic breast cancer (m...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2024
|
| In: |
The oncologist
Year: 2024, Jahrgang: 29, Heft: 9, Pages: 768-779 |
| ISSN: | 1549-490X |
| DOI: | 10.1093/oncolo/oyae088 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/oncolo/oyae088 Verlag, kostenfrei, Volltext: https://academic.oup.com/oncolo/article/29/9/768/7674171 
|
| Verfasserangaben: | Hope S Rugo, Peter Schmid, Sara M Tolaney, Florence Dalenc, Frederik Marmé, Ling Shi, Wendy Verret, Anuj Shah, Mahdi Gharaibeh, Aditya Bardia, Javier Cortes |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1911219359 | ||
| 003 | DE-627 | ||
| 005 | 20250716214752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/oncolo/oyae088 |2 doi | |
| 035 | |a (DE-627)1911219359 | ||
| 035 | |a (DE-599)KXP1911219359 | ||
| 035 | |a (OCoLC)1528014648 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rugo, Hope S. |e VerfasserIn |0 (DE-588)1020214171 |0 (DE-627)691143218 |0 (DE-576)359869203 |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial |c Hope S Rugo, Peter Schmid, Sara M Tolaney, Florence Dalenc, Frederik Marmé, Ling Shi, Wendy Verret, Anuj Shah, Mahdi Gharaibeh, Aditya Bardia, Javier Cortes |
| 264 | 1 | |c September 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 15. Mai 2024 | ||
| 500 | |a Gesehen am 09.12.2024 | ||
| 520 | |a The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician’s choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2−) metastatic breast cancer (mBC). Here, we present health-related quality of life (HRQoL) patient-reported outcome (PRO) findings from this study.Eligible adults with HR+/HER2− mBC who previously received a taxane, endocrine-based therapy, a CDK4/6 inhibitor, and 2-4 lines of chemotherapy were randomized 1:1 to receive SG or TPC until progression or unacceptable toxicity. PROs were assessed at baseline and on day 1 of each cycle, using the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 (EORTC QLQ-C30), EQ-5D-5L, and PRO Common Terminology Criteria for Adverse Events (PRO-CTCAE).Compared to TPC, overall least square mean change from baseline was significantly better for SG for physical functioning and dyspnea, but worse for diarrhea. Time to first clinically meaningful worsening or death was significantly longer for SG in global health status/quality of life, physical functioning, fatigue, emotional functioning, dyspnea, insomnia, and financial difficulties of the EORTC QLQ-C30 and the EQ-VAS, but longer for TPC in diarrhea. Few patients in both arms reported experiencing any worsening to level 3 or 4 treatment-related symptomatic events during treatment, as assessed by 16 PRO-CTCAE items, except for diarrhea frequency and amount of hair loss, which favored TPC.SG was associated with an HRQoL benefit in most symptoms and functioning, compared with TPC. This supports the favorable profile of SG as a treatment option for patients with pretreated HR+/HER2− mBC. | ||
| 700 | 1 | |a Schmid, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tolaney, Sara M |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dalenc, Florence |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Shi, Ling |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verret, Wendy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shah, Anuj |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gharaibeh, Mahdi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bardia, Aditya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortes, Javier |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d Oxford : Oxford University Press, 1996 |g 29(2024), 9, Seite 768-779 |h Online-Ressource |w (DE-627)32063020X |w (DE-600)2023829-0 |w (DE-576)281196338 |x 1549-490X |7 nnas |a Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:9 |g pages:768-779 |g extent:12 |a Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1093/oncolo/oyae088 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/oncolo/article/29/9/768/7674171 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241209 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1911219359 |e 4633380885 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"September 2024","dateIssuedKey":"2024"}],"note":["Online veröffentlicht: 15. Mai 2024","Gesehen am 09.12.2024"],"title":[{"title":"Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial","title_sort":"Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1911219359","relHost":[{"language":["eng"],"part":{"pages":"768-779","year":"2024","text":"29(2024), 9, Seite 768-779","issue":"9","extent":"12","volume":"29"},"note":["Gesehen am 19.04.2022"],"origin":[{"dateIssuedDisp":"1996-","publisher":"Oxford University Press ; AlphaMed Press ; Wiley","dateIssuedKey":"1996","publisherPlace":"Oxford ; Miamisburg, Ohio ; Hoboken, NJ"}],"pubHistory":["1.1996 -"],"title":[{"title":"The oncologist","subtitle":"the international peer-reviewed journal for the practicing oncologist, hematologist","title_sort":"oncologist"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trialThe oncologist","physDesc":[{"extent":"Online-Ressource"}],"recId":"32063020X","id":{"eki":["32063020X"],"doi":["10.1002/(ISSN)1549-490X"],"zdb":["2023829-0"],"issn":["1549-490X"]}}],"name":{"displayForm":["Hope S Rugo, Peter Schmid, Sara M Tolaney, Florence Dalenc, Frederik Marmé, Ling Shi, Wendy Verret, Anuj Shah, Mahdi Gharaibeh, Aditya Bardia, Javier Cortes"]},"physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"id":{"eki":["1911219359"],"doi":["10.1093/oncolo/oyae088"]},"person":[{"display":"Rugo, Hope S.","family":"Rugo","role":"aut","given":"Hope S."},{"display":"Schmid, Peter","family":"Schmid","given":"Peter","role":"aut"},{"role":"aut","given":"Sara M","family":"Tolaney","display":"Tolaney, Sara M"},{"display":"Dalenc, Florence","family":"Dalenc","role":"aut","given":"Florence"},{"role":"aut","given":"Frederik","family":"Marmé","display":"Marmé, Frederik"},{"given":"Ling","role":"aut","family":"Shi","display":"Shi, Ling"},{"role":"aut","given":"Wendy","display":"Verret, Wendy","family":"Verret"},{"given":"Anuj","role":"aut","display":"Shah, Anuj","family":"Shah"},{"role":"aut","given":"Mahdi","display":"Gharaibeh, Mahdi","family":"Gharaibeh"},{"family":"Bardia","display":"Bardia, Aditya","given":"Aditya","role":"aut"},{"display":"Cortes, Javier","family":"Cortes","given":"Javier","role":"aut"}],"language":["eng"]} | ||
| SRT | |a RUGOHOPESSHEALTHRELA2024 | ||